QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-reiterates-outperform-on-tarsus-pharmaceuticals-raises-price-target-to-63

Oppenheimer analyst Francois Brisebois reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the pric...

 tarsus-pharmaceuticals-q2-2024-gaap-eps-088-beats-094-estimate-sales-40813m-beat-31664m-estimate

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate o...

 hc-wainwright--co-maintains-buy-on-tarsus-pharmaceuticals-raises-price-target-to-61

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price t...

 barclays-maintains-overweight-on-tarsus-pharmaceuticals-raises-price-target-to-60

Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and raises the price target ...

 oppenheimer-maintains-outperform-on-tarsus-pharmaceuticals-raises-price-target-to-61

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price...

 tarsus-pharmaceuticals-q1-2024-gaap-eps-101-beats-120-estimate-sales-27614m-beat-17460m-estimate

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate o...

 tarsus-prices-100m-public-offering-of-2812500-common-shares-at-32share

Tarsus Pharmaceuticals announced the pricing of an underwritten public offering of 2,812,500 shares of its common stock at a pu...

 tarsus-pharmaceuticals-reveals-proposed-100m-public-offering

Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its co...

 goldman-sachs-maintains-neutral-on-tarsus-pharmaceuticals-raises-price-target-to-30

Goldman Sachs analyst Andrea Tan maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral and raises the price target f...

 hc-wainwright--co-maintains-buy-on-tarsus-pharmaceuticals-raises-price-target-to-57

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price t...

 barclays-maintains-overweight-on-tarsus-pharmaceuticals-raises-price-target-to-50

Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and raises the price target ...

 icu-medical-to-rally-around-28-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 oppenheimer-reiterates-outperform-on-tarsus-pharmaceuticals-raises-price-target-to-59

Oppenheimer analyst Francois Brisebois reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION